Quick Answer
International Stem Cell CORP reported Revenue (ASC 606) of $9.10 million for fiscal year 2025.
International Stem Cell CORP Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $9.10M | +0.2% |
| 2024 | $9.09M | +16.6% |
| 2023 | $7.79M | -4.8% |
| 2022 | $8.18M | +14.0% |
| 2021 | $7.18M | +0.7% |
| 2020 | $7.13M | -24.7% |
| 2019 | $9.47M | -14.6% |
| 2018 | $11.09M | +48.7% |
| 2017 | $7.46M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.37M | +8.7% | -3.2% |
| June 30, 2025 | $2.45M | +5.0% | +14.9% |
| March 31, 2025 | $2.13M | +0.0% | -2.3% |
| September 30, 2024 | $2.18M | +10.4% | -6.5% |
| June 30, 2024 | $2.33M | +26.6% | +9.5% |
| March 31, 2024 | $2.13M | +2.1% | +7.9% |
| September 30, 2023 | $1.97M | +15.9% | +7.2% |
| June 30, 2023 | $1.84M | -9.2% | -11.7% |
- International Stem Cell CORP showed an increase of +0.2% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2017–2025 period, International Stem Cell CORP’s revenue (asc 606) has grown by 22.0% (from $7.46 million to $9.10 million).
- The most recent figure is from International Stem Cell CORP’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: